ライフサイエンスコーパス: transfusion

1 immunospot assay before convalescent plasma transfusion.

2 19 pandemic has major implications for blood transfusion.

3 associated with greater odds of receiving a transfusion.

4 outcome was clinical status at day 14 after transfusion.

5 3 months or because they had a recent blood transfusion.

6 recipient neutralizing activity 1 day after transfusion.

7 ce in other clinical outcomes, regardless of transfusion.

8 sfusion INR, and decreased component product transfusion.

9 ely been matched by reductions in demand for transfusion.

10 8513 (32.8%) patients received a blood transfusion.

11 0%) of 17 380 patients who did not receive a transfusion.

12 nt for baseline characteristics and platelet transfusion.

13 p, respectively), with similar time to first transfusion.

14 lls in response to allogeneic red-blood-cell transfusion.

15 ticagrelor cannot be reversed with platelet transfusion.

16 of days; and 68% received at least one blood transfusion.

17 d the proportion of patients receiving blood transfusion.

18 ified pairs of patients with and without RBC transfusion.

19 ctive generally become dependent on red-cell transfusions.

20 in similar HRQOL and HCT outcomes with fewer transfusions.

21 oxicities were managed by dose reduction and transfusions.

22 a and sickle cell anemia, or following blood transfusions.

23 s well as increased risk of allogeneic blood transfusions.

24 cations associated with red blood cell (RBC) transfusions.

25 e deficiency who were not receiving red-cell transfusions.

26 ombocytopenia requiring one or more platelet transfusions.

27 ndent beta-thalassemia need regular red-cell transfusions.

28 rane oxygenation were free of any hemostatic transfusions.

29 disease severity of patients who received a transfusion (0.50 [0.42-0.60]).

30 bleeding (16.7% versus 21.0%; P<0.001), and transfusion (10.3% versus 18.5%; P<0.001), but higher va

31 requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse af

32 By day 14 after transfusion, 19 (76%) patients had at least a one-point

33 -arginine vasopressin (0.4 ug/kg) + platelet transfusion (2 U) within 60 minutes of intracerebral hem

34 e series of 100 patients up to 2 months post transfusion, 28 of whom were obtained from chart review

35 jection drug, 33.3% who had history of blood transfusion, 29.8% who had sexual experience, 21.2% who

36 two sequential ABO-compatible fresh platelet transfusions; (3) hepatomegaly is best defined as an abs

37 s 5.5%, P < 0.0001), require a massive blood transfusion (43.5% vs 1.1%, P < 0.0001), or require dama

38 Postoperative transfusion (8.28 vs. 7.50%, p = .057) and mortality (2.

39 ions per million (106) packed red blood cell transfusions (95% CI, 0.29-0.65 transmissions/106 transf

40 nsfusions) before and 0.35 transmissions/106 transfusions (95% CI, 0.31-0.65 transmissions/106 transf

41 stroke, life-threatening bleeding requiring transfusion, acute kidney injury requiring dialysis, or

42 s (in-hospital mortality, bleeding requiring transfusion, acute kidney injury, stroke, length of stay

43 ensus on the benefit of red blood cell (RBC) transfusion after transcatheter aortic valve replacement

44 fusions (95% CI, 0.31-0.65 transmissions/106 transfusions) after implementation.

45 suggests that national transplant and blood transfusion agencies work together to develop a co-ordin

46 Within 48 hours of transfusion, all but 1 patient experienced an improvemen

47 splant patients (46 who developed a DSA post transfusion and 40 who remained DSA negative) were HLA t

48 tudy was to estimate the association between transfusion and death among children admitted to hospita

49 nt rates associated with IV iron vs red cell transfusion and discuss using first-line IV iron monothe

50 sing in older patients; in most cases, blood transfusion and hospitalization are required.

51 Interaction testing between RBC transfusion and mortality was not statistically signific

52 on, total procedural duration, blood product transfusion and salvages a small subset of patients who

53 ety of practice recommendations to limit RBC transfusion and tolerate anemia during and after hospita

54 al stay, costs of warming blanket use, blood transfusions and antibiotics used in the operating room,

55 Minimizing EBL has been shown to decrease transfusions and provide better perioperative outcomes i

56 asts who had been receiving regular red-cell transfusions and who had disease that was refractory to

57 outcome, including hemostatic intervention, transfusion, and in-hospital mortality, were compared wi

58 roteins limit successful transplantation and transfusion, and their presence in blood products can ca

59 2, portal hypertension, intraoperative blood transfusions, and center's volume.

60 d correct anaemia, reduce the need for blood transfusions, and improve patient outcomes.

61 asive ventilation (NIV), simple and exchange transfusions, and the presence of bilateral pleural effu

62 Bleeding, blood product transfusions, and thrombosis were not different in the t

63 res (AOR = 1.41, p < 0.001), including blood transfusion (AOR = 4.7, p < 0.001); hospital admission (

64 Red blood cell transfusions are commonly administered to infants weighi

65 RBCs would have inferior storage quality for transfusion as compared with G6PD-normal RBCs.METHODSMal

66 Participants received transfusions as deemed necessary by the treating physici

67 f related SAEs, including mortality (n = 4), transfusion-associated circulatory overload (n = 7), tra

68 The definition of transfusion-associated circulatory overload varied among

69 ed methods to enhance accuracy for detecting transfusion-associated pathogens sharing taxonomic simil

70 ed methods to enhance accuracy for detecting transfusion-associated pathogens that share taxonomic si

71 48 hours after delivery to receive red-cell transfusions at higher or lower hemoglobin thresholds un

72 fusions (95% CI, 0.29-0.65 transmissions/106 transfusions) before and 0.35 transmissions/106 transfus

73 nt complications, with packed red blood cell transfusions being the most common intervention during r

74 enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units t

75 ficacy end points included reductions in the transfusion burden during any 12-week interval and resul

76 ntage of patients who had a reduction in the transfusion burden of at least 33% from baseline during

77 ntage of patients who had a reduction in the transfusion burden of at least 33% from baseline during

78 ercentage of patients who had a reduction in transfusion burden of at least 33% was greater in the lu

79 dent beta-thalassemia who had a reduction in transfusion burden was significantly greater in the lusp

80 ent patients achieved >=20% reduction in RBC transfusion burden.

81 ells (RBCs) are needed for life-saving blood transfusions, but they undergo continuous degradation.

82 efinitely related to the convalescent plasma transfusion by the treating physician.

83 RBC transfusions can increase oxygen availability to the tis

84 In 3 gram-negative septic transfusion cases, we performed metagenomic next-generat

85 searched for relevant studies addressing the transfusion chain-from donor, through collection and pro

86 ess than 1000 g, a strategy of liberal blood transfusions compared with restrictive transfusions did

87 This transfusion complication can only be remedied when the i

88 RBC transfusion correlates with increased mortality and acut

89 ewpoint, we discuss the relationship between transfusion dependence and hospice use for patients with

90 clinical trial using enasidenib to decrease transfusion dependence in a wide array of clinical conte

91 Transfusion-dependent beta-thalassemia (TDT) and sickle

92 ccur via several mechanisms in patients with transfusion-dependent beta-thalassemia (TDT) mainly chro

93 Patients with transfusion-dependent beta-thalassemia need regular red-

94 al, we assigned, in a 2:1 ratio, adults with transfusion-dependent beta-thalassemia to receive best s

95 The percentage of patients with transfusion-dependent beta-thalassemia who had a reducti

96 Transfusion-dependent haemoglobinopathies require lifelo

97 In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone w

98 ric patients (aged 1 month to 18 years) with transfusion-dependent haemoglobinopathies.

99 o oral chelators used in adult patients with transfusion-dependent haemoglobinopathies.

100 Of 21 transfusion-dependent patients (63.6%) at baseline, 9 (4

101 Twenty-six (81%) transfusion-dependent patients achieved >=20% reduction

102 ed, but the need for chronic transfusions in transfusion-dependent thalassemia (TDT) and iron chelati

103 , a higher hemoglobin threshold for red-cell transfusion did not improve survival without neurodevelo

104 ed clinical trial that prophylactic platelet transfusion did not reduce clinical bleeding.

105 blood transfusions compared with restrictive transfusions did not reduce the likelihood of death or d

106 405 (4.8%) of 8513 patients who received a transfusion died compared with 689 (4.0%) of 17 380 pati

107 tients with poor platelet recovery, platelet transfusion does not improve outcomes and may actually i

108 Daily plasma transfusion dose was independently associated with chest

109 Daily platelet transfusion dose was independently associated with chest

110 Daily cryoprecipitate transfusion dose was independently associated with young

111 nimal transplant models using donor-specific transfusions (DST) has previously required additional im

112 lines advocate to limit red blood cell (RBC) transfusion during surgery, but the feasibility and safe

113 intain ongoing equitable access to blood for transfusion during the pandemic, in addition to providin

114 d therapy without need for dose reduction or transfusion; eight required two or more courses of thera

115 an increase in mean oxygen consumption after transfusion, especially in patients with sepsis.

116 Investigating septic transfusion events is often restricted by the limitation

117 Investigation of septic transfusion events is often restricted by the limitation

118 By using in vivo imaging and transfusion experiments, we further confirmed that senes

119 of difference in incidence of red blood cell transfusion for a titration-dose strategy versus a fixed

120 ia, we evaluated incidence of red blood cell transfusions for participants randomized to receive darb

121 Plasma transfusion from Apom transgenic mice but not Apom knock

122 od transfusion or death, and number of blood transfusions from randomisation to 30 days postoperative

123 Of these, 188 were randomly assigned to the transfusion group and 184 to the control group.

124 r use of blood components compared with SOC (transfusion guided by INR and PLT count), without an inc

125 ns who were aware of local and international transfusion guidelines.

126 fetus transmission, sexual contact and blood transfusion, have also been observed(3-7).

127 After HCT, mean pre-transfusion Hb levels were 70.9 g/L in the restrictive-s

128 Prevention of HCV infection through blood transfusion, HCV treatment and adequate iron chelation a

129 ct percutaneous exposure to blood, via blood transfusions, health-care-related injections, and inject

130 est no hemostatic efficacy of early platelet transfusion in intracerebral hemorrhage under antiplatel

131 ts use may avoid unnecessary blood component transfusion in patients with advanced cirrhosis and sign

132 al, a key barrier is limited access to blood transfusions in hospice programmes.

133 through a bite of an infected tick and blood transfusions in human.

134 There were 111 blood transfusions in the placebo group and 105 in the intrave

135 recently increased, but the need for chronic transfusions in transfusion-dependent thalassemia (TDT)

136 nce rate ratio, 0.27; 95% CI, 0.11 to 0.56), transfusions (incidence rate ratio, 0.30; 95% CI, 0.20 t

137 resent at high frequency on red blood cells, transfusion incompatibility problems, due to the absence

138 ough 24, and the key secondary end point was transfusion independence for 12 weeks or longer, assesse

139 The primary end point was transfusion independence for 8 weeks or longer during we

140 Transfusion independence for 8 weeks or longer was obser

141 tolerated and induced durable remissions and transfusion independence in patients with newly diagnose

142 oglobin that were distributed pancellularly, transfusion independence, and (in the patient with SCD)

143 unexpected improvement in hemoglobin and RBC transfusion-independence in patients with acute myeloid

144 tients (63.6%) at baseline, 9 (42.9%) became transfusion independent. IDH1 mutation clearance was see

145 The post-transfusion INR was decreased in whole blood vs componen

146 ts in faster resolution of shock, lower post-transfusion INR, and decreased component product transfu

147 There are uncertain patterns of demand, and transfusion institutions need to plan for reductions in

148 Platelet transfusion is common in dengue patients with thrombocyt

149 Blood transfusion is fundamental in managing hematologic malig

150 e-while reducing the need for red blood cell transfusions-is unknown.

151 ibility, donor recruitment, collections, and transfusion itself.

152 and fatigue, or we do treat it through blood transfusions, leading to iron overload, which is a quite

153 at higher hemoglobin thresholds for red-cell transfusions may reduce the risk of cognitive delay amon

154 e data suggest novel mechanisms by which RBC transfusion mediates inflammatory and/or thrombotic outc

155 nd erythrocyte under cold storage for use in transfusion medicine.

156 ology, hepatology, radiology, pathology, and transfusion medicine; HSCT advanced-practice providers a

157 Blood transfusion might benefit some patients with malaria but

158 We therefore aimed to estimate the blood transfusion need and supply at national level to determi

159 Death or blood transfusion occurred in 67 (28%) of the 237 patients in

160 ly to bleed if given a prophylactic platelet transfusion (odds ratio 2.34, 95% confidence interval 1.

161 .01-1.05]; p = 0.007), intraoperative plasma transfusion (odds ratio, 1.13 [95% CI, 1.02-1.26]; p = 0

162 1%] with malaria) were assigned to receive a transfusion of 30 ml per kilogram (1598 children) or 20

163 DSThus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescen

164 mouse model of multiple sclerosis, that the transfusion of autologous regulatory B cells (B(regs)) i

165 We have found that transfusion of B(regs) reverses established clinical EAE

166 It is transmitted by Ixodes ticks, transfusion of blood and blood products, organ donation,

167 Transfusion of blood, or more commonly red blood cells (

168 Transfusion of convalescent plasma collected from donors

169 For over a century, transfusion of convalescent plasma from recovered indivi

170 These early indicators suggest that transfusion of convalescent plasma is safe in hospitaliz

171 Passive antibody administration through transfusion of convalescent plasma may offer the only sh

172 he antiviral drug remdesivir, dexamethasone, transfusion of convalescent plasma, and use of antithrom

173 xtends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalizat

174 A single transfusion of F1 splenocytes into B6 mice without any a

175 iated with an increased risk of VTE, whereas transfusion of fresh frozen plasma had no effect.

176 his increased susceptibility is abrogated by transfusion of HYAL2-competent platelets.

177 As a consequence, parabiosis or transfusion of monocytic cells results in long-term gene

178 ycytidilic acid (poly[I:C]), followed by the transfusion of murine red blood cells (RBCs) expressing

179 (15.4%) experienced bleeding that required a transfusion of packed RBCs.

180 At present, judicious transfusion of RBCs is the primary strategy invoked in a

181 ing maxim in clinical medicine that a 1-unit transfusion of red blood cells (RBCs) should yield a pos

182 anti-RBD IgG titer facilitated selection and transfusion of the highest titer units available.

183 Transfusion of whole blood in pediatric trauma patients

184 tic review and meta-analysis, the effects of transfusion on hemodynamic/oxygenation variables in pati

185 by 160% during this time, and SMM excluding transfusion-only cases increased by 53%.

186 SMM rate, total and without transfusion-only cases; 2019 maternal comorbidity index.

187 were risk of the composite outcome of blood transfusion or death, and number of blood transfusions f

188 ite endpoint of hospital-based intervention (transfusion or hemostatic intervention) or death within

189 ather than constraining patients into either transfusion or hospice models, policies that promote com

190 acute renal dysfunction, bleeding requiring transfusion or intervention, hypotension (systolic arter

191 d not significantly change the rate of blood transfusions or occurrence of cardiac tamponade.

192 nd total antibody titers before and after CP transfusion over a 14-day period in hospitalized patient

193 ut (p < 0.001), other bleeding requiring RBC transfusion (p = 0.01), activated clotting time (p = 0.0

194 ut (p < 0.001), other bleeding requiring RBC transfusion (p = 0.03), and daily set platelet goal (p =

195 ing (p = 0.18), other bleeding requiring RBC transfusion (p = 0.75), fibrinogen level (p = 0.67), or

196 (P=0.044), major bleeding (P=0.041), and RBC transfusion (P=0.048) were independent correlates of 30-

197 nt interaction between platelet recovery and transfusion; patients with poor platelet recovery were m

198 a major hemorrhage management on outcome and transfusion practice, and to determine the contemporary

199 Evidence regarding red blood cell (RBC) transfusion practices and their impact on hematopoietic

200 Individual transfusion professionals were then invited to assess 24

201 -free days, ventilation-free days, and blood transfusion proportion.

202 Massive transfusion protocols are the mainstay of treatment for

203 actions between these randomisations or with transfusion randomisations (p>0.2).

204 an blood loss (300, 250, 200 mL, P < 0.001), transfusion rate (19%, 15%, 5%, P < 0.001), median lengt

205 udy, we estimated the ideal disease specific-transfusion rate as the lowest rate from the years 2000

206 hropoiesis are urgently required to decrease transfusion rates and improve quality of life.

207 Implementation of PBM significantly reduced transfusion rates by 39% [risk ratio (RR) 0.61, 95% conf

208 Transfusion rates did not change.

209 Intra-, post-, and perioperative transfusion rates were 15.8%, 24.8%, and 37.2%, respecti

210 te lung injury (n = 11), and severe allergic transfusion reactions (n = 3).

211 nditions such as sickle cell anemia, sepsis, transfusion reactions, medical-device associated hemolys

212 A total of 244 blood donors of transfusions received by 86 transplant patients (46 who

213 pproach as a tool to design patient-specific transfusion regimens.

214 ion-associated circulatory overload (n = 7), transfusion-related acute lung injury (n = 11), and seve

215 presence in blood products can cause lethal transfusion-related acute lung injury (TRALI).

216 on of pathogens responsible for each case of transfusion-related sepsis and enabled discovery of a no

217 Transfusion-related sepsis remains an important hospital

218 Variability in the timing of transfusion relative to admission and titer of antibodie

219 The multicenter Transfusion Requirements in Transcatheter Aortic Valve I

220 MDS are characterized by anemia and transfusion requirements.

221 ome; serious infections; WHO Bleeding Scale; transfusion requirements; and reactions to therapy.

222 mpared to component transfusion, whole blood transfusion results in faster resolution of shock, lower

223 nce in first-time blood donors or associated transfusion risk increased.

224 ral weeks after a second convalescent plasma transfusion, SARS-CoV-2 RNA was no longer detected.

225 reporting the sequence: DBA, multiple blood transfusions, secondary haemochromatosis, advanced liver

226 the basis of evolving publications will help transfusion services and hospitals in countries at diffe

227 upply at national level to determine gaps in transfusion services globally.

228 cation, injection drug use, history of blood transfusion, sexual experience, shaving equipment sharin

229 atment approaches are supportive and include transfusions, splenectomy, and chelation.

230 olled in the study, 25 893 of whom had their transfusion status recorded and were included in the pri

231 ted to evaluate the appropriateness of these transfusion strategies.

232 differences in clinical outcomes between the transfusion strategies.

233 ource) were randomly allocated to TEG-guided transfusion strategy (TEG group; n = 49) or standard-of-

234 g/L) or liberal (Hb threshold < 90 g/L) RBC transfusion strategy between day 0 and day 100.

235 nd nonvariceal upper GI bleeding, TEG-guided transfusion strategy leads to a significantly lower use

236 undergoing HCT, the use of a restrictive RBC transfusion strategy threshold of 70 g/L was as effectiv

237 ucing surgical blood loss such as autologous transfusion techniques and agents to optimize hemostasis

238 For hemoglobin increments 24 hours after transfusion, the coefficient of determination for the ge

239 he increasing use of hydroxyurea, in lieu of transfusion therapy, for SCD patients with abnormal tran

240 o be used to inform selection of the optimal transfusion therapy.

241 in the TEG group received no blood component transfusion, there were no such patients in the SOC grou

242 ents (40%) had grade 3 anemia and required a transfusion, three patients had grade 3 neutropenia, and

243 d overall benefit of a prophylactic platelet transfusion threshold of 25 x 109/L compared with 50 x 1

244 ncentrations above the currently recommended transfusion threshold.

245 randomised controlled trials to test higher transfusion thresholds among African children with sever

246 492) or restrictive (n = 521) red blood cell transfusion thresholds based on infants' postnatal age a

247 Among infants in the liberal vs restrictive transfusion thresholds groups, respectively, incidence o

248 Evidence-based transfusion thresholds have not been established.

249 bjective was to estimate optimal haemoglobin transfusion thresholds using generalised additive models

250 tes of cognitive impairment with restrictive transfusion thresholds.

251 om 140 to 190 mm Hg), anemia requiring blood transfusions, thrombocytopenia, and pneumonia.

252 atients with acute COVID-19 before and after transfusion through the traditional Food and Drug Admini

253 , so she had been submitted to monthly blood transfusions throughout her life, leading to a hepatitis

254 cement therapy, postoperative red blood cell transfusions, time to first extubation, time to discharg

255 Additionally, blood transfusions to correct anaemia exposes children to safe

256 ps and symptomatic anemia requiring lifelong transfusions to fully compensated hemolysis.

257 using dose-escalated hydroxyurea and regular transfusions to prevent complications of sickle cell ane

258 asts who had been receiving regular red-cell transfusions to receive either luspatercept (at a dose o

259 d a restrictive threshold for red blood cell transfusion (transfuse if hemoglobin<7.5 g/dl, intraoper

260 tuations could lead to increased risk of HIV transfusion transmission if blood screening assays are u

261 observed no increase in HIV incidence or HIV transfusion transmission risk after implementation of a

262 Residual transfusion transmission risk was estimated by multiplyi

263 The residual risk of HIV transfusion transmission through components sourced from

264 However, their use could affect HIV transfusion-transmission risk.

265 oral sequence of events associated with each transfusion-transmitted infection.

266 o advance existing methods for investigating transfusion-transmitted infections.

267 sed blood collection and adherence to strict transfusion triggers as strategies to improve blood avai

268 After adjusting for transfusion type and baseline FACT-BMT score, the restri

269 iotomy, acute kidney injury, major bleeding, transfusion, vascular complications, length of stay, and

270 In line with the randomized Platelet Transfusion Versus Standard Care After Acute Stroke Due

271 the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for sev

272 lity rate (0.3%), in the first 4 hours after transfusion was <1%.

273 holds groups, respectively, incidence of any transfusion was 400/492 (81.3%) vs 315/521 (60.5%); medi

274 Among 2587 patients, RBC transfusion was administered in 421 cases (16%).

275 e increase in mean oxygen delivery following transfusion was associated with an increase in mean oxyg

276 Transfusion was associated with decreased odds of death

277 Our findings suggest that whole blood transfusion was associated with improved survival among

278 impaired consciousness or hyperlactataemia, transfusion was associated with improved survival at hae

279 red consciousness (Blantyre Coma Score <=4), transfusion was associated with improved survival at hae

280 Among all study participants, transfusion was associated with improved survival when t

281 In the 842 propensity-matched patients, RBC transfusion was associated with increased mortality (haz

282 Transfusion was not associated with a decrease in mean c

283 -deamino-8-D-arginine vasopressin + platelet transfusion was not associated with the 3-month function

284 perlactataemia (blood lactate >=5.0 mmol/L), transfusion was not significantly associated with harm a

285 e heterozygous individual infected via blood transfusion was reported, and we established that the sp

286 % CIs comparing the periods before and after transfusion were -0.0 L/min/m (-0.1 to 0.1 L/min/m) (p =

287 No adverse events as a result of plasma transfusion were observed.

288 Although most hemostatic transfusions were independently associated with bleeding

289 superior to placebo to reduce need for blood transfusion when administered to patients with anaemia 1

290 e primary endpoint was death associated with transfusion, which was estimated using models adjusted f

291 Blood transfusion (whole blood at a target volume of 20 mL per

292 Compared to component transfusion, whole blood transfusion results in faster r

293 utes to the ultimate goal of replacing blood transfusion with a manufactured product.

294 At day 7 after transfusion with convalescent plasma, nine patients had

295 , policies that promote combining palliative transfusions with hospice services are likely to optimis

296 ive to a dose-titration approach to minimize transfusions, with less cumulative dosing.

297 re also less likely to receive blood product transfusions within 24 hours of testing compared with th

298 nts of enzyme but enabled proof-of-principle transfusions without adverse effects in humans.

299 cytopenia (59% v 9%; P < .0001) and platelet transfusions without bleeding (35% v 0%; P = .0002), but

300 Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versu